Genprex licenses NYU patent for Reqorsa gene therapy in mesothelioma; TUSC2 down in 84%

Genprex, Inc.

Exclusive patent license with NYU Langone Health for Reqorsa (quaratusugene ozeplasmid) to treat mesothelioma.
TUSC2 tumor suppressor gene is downregulated in 84% of mesotheliomas; Reqorsa delivers TUSC2.
Preclinical data showed decreased cell proliferation/invasion and increased apoptosis in all four MPM cell lines.
Genprex formed a Mesothelioma Clinical Advisory Board of four leading researchers to guide the program.
About 3,000 new US cases/yr; life expectancy 18 months, 3-year survival rate 23% with treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.